AK138D1 with or without ivonescimab for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This early-stage trial tests a new immunotherapy drug called AK138D1, given alone or combined with another drug (ivonescimab), to treat advanced breast cancer. The study aims to find the right dose and see if this combination helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Advanced (metastatic) breast cancer that can be measured on imaging
- Good overall health and ability to manage daily activities (ECOG 0–1)
- Expected to live at least 3 months
- Normal organ function (liver, kidney, heart, blood counts)
- Not enrolled in another drug study, though follow-up visits from past studies are okay
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (AK112) combined with chemotherapy as a first treatment for advanced esophageal cancer that has spread or cannot be removed. It aims to see if this combination helps shrink tumors and controls the disease longer than chemotherapy alone.
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
This trial tests an experimental drug called AK138D1, either by itself or combined with another drug (ivonescimab), for people with advanced non-small cell lung cancer that has spread. It aims to see if these treatments are safe and effective.
This trial tests a new drug called AK138D1 for people with advanced solid tumors. It aims to see if the drug is safe and how well it works, especially for tumors that haven't been treated with HER3-targeted therapy before.
This trial tests a new drug called AK138D1 for people with advanced solid tumors that have not responded to or can't tolerate standard treatments. The goal is to see if it is safe and effective.
This phase 1 trial tests a new drug called AK137, which is designed to help your immune system better attack cancer cells. It is for people with advanced tumors that have not been helped by standard therapies. The goal is to find out if AK137 is safe and effective.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.